Learn more about Peter Attia’s digital program
#272 ‒ Rapamycin: potential longevity benefits, surge in popularity, unanswered questions, and more | David Sabatini, M.D., Ph.D. and Matt Kaeberlein, Ph.D.
“[Rapamycin] is the most robust and reproducible drug that we know about today for impacting not only longevity, but to the extent that we can measure various metrics of healthspan in complex animals, rapamycin also seems to positively impact pretty much every aspect of health span that we measure.” —Matt Kaeberlein
#175 – Matt Kaeberlein, Ph.D.: The biology of aging, rapamycin, and other interventions that target the aging process
“I don’t think I will ever understand aging fully. And I don’t think the field will. … But I also believe that we don’t have to understand it fully to be able to have an impact on the biology of aging through interventions.” —Matt Kaeberlein